U.S. Arm Of Indian Glenmark Settles Patent Suits With Teva
This article was originally published in PharmAsia News
Executive Summary
The U.S. subsidiary of India's Glenmark Pharmaceuticals and Israel's Teva have settled a patent dispute in a U.S. court involving Teva's Coreg (carvedilol) for treating congestive heart failure. Glenmark Generics had used a process patent to prepare the compound, sparking a suit by Teva, and Glenmark responded with a challenge of its own against two Teva patents for Coreg. The two companies settled their disputes out of court and the judge in the case accepted. Two other Indian drug makers, Ranbaxy and Dr. Reddy's, earlier settled out of court with Teva over the same drug. (Click here for more